PressJune 1, 2023 Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study
PressMay 30, 2023 Filament Health Announces Interim Results from Phase I Clinical Trial at the University of California San Francisco
PressMay 30, 2023 Psilera Unveils Novel, Non-Hallucinogenic Psilocybin Derivative PSIL-006 As Lead Clinical Candidate
PressMay 26, 2023 MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
PressMay 26, 2023 MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
PressMay 26, 2023 Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
PressMay 26, 2023 MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
PressMay 26, 2023 FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors
PressMay 26, 2023 Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD)
PressMay 26, 2023 Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy
PressMay 23, 2023 MAPS-Sponsored Global Psychedelic Survey Gathers Data for a Crucial View into Psychedelic Use
PressMay 23, 2023 Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
PressMay 19, 2023 MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
PressMay 18, 2023 Filament Health Announces First Ever Nagoya Protocol-Compliant Shipment of Iboga from Gabon
PressMay 18, 2023 Optimi Health Completes Harvest Of Psilocybe Cubensis For Delivery To The Australian Medical Market
